p27kip1 is a cyclin-dependent kinase inhibitor that regulates progression from G1 into S phase. Aberrations in cell cycle control are often observed in tumors d might even be necessary in tumor development. Recent reports showed that low 7kip1 expression is associated with poor prognosis in several tumors and ukemia. To investigate the expression of p27kip1 in malignant lymphomas and ucidate the role of p27kip1 as a possible prognostic indicator, the authors rformed an immunohistochemical staining of p27kip1 correlated with Ki-67 belling index and clinical parameters. p27kip1 expression was reduced variably most malignant lymphomas and inversely correlated with Ki-67 labelling index +AD0-0.0151). Regarding chemotherapeutic response, p271kip1 expression in the mplete remission group showed statistically significant difference in pression compared to the progressive disease group (p+AD0-0.0021). There were gnificant differences in survival between cases with low and high p27kip1 pression (p+AD0-0.0071). In a multivariate Cox analysis, p27kip1 expression was dependent prognostic factors as well as other known prognostic factors cluding age, grade, stage and chemotherapeutic response. In conclusion, the udy suggests that reduced expression of p27kip1 protein may play a role in the thogenesis and biologically aggressive behavior of malignant lymphomas.
Adolescence ; Adult ; Aged ; Antineoplastic Agents, Combined/therapeutic use ; Cell Cycle ; Cell Division ; Child ; Child, Preschool ; Comparative Study ; Female ; Follow-Up Studies ; Human ; Ki-67 Antigen/analysis ; Life Tables ; Lymphoma, Non-Hodgkin/pathology ; Lymphoma, Non-Hodgkin/mortality ; Lymphoma, Non-Hodgkin/drug therapy ; Lymphoma, Non-Hodgkin/chemistry+ACo- ; Male ; Microtubule-Associated Proteins/physiology ; Microtubule-Associated Proteins/analysis+ACo- ; Middle Age ; Neoplasm Proteins/physiology ; Neoplasm Proteins/analysis+ACo- ; Prognosis ; Proportional Hazards Models ; Survival Analysis ; Treatment Outcome

p27kip1 is a cyclin-dependent kinase inhibitor that regulates progression from G1 into S phase. Aberrations in cell cycle control are often observed in tumors d might even be necessary in tumor development. Recent reports showed that low 7kip1 expression is associated with poor prognosis in several tumors and ukemia. To investigate the expression of p27kip1 in malignant lymphomas and ucidate the role of p27kip1 as a possible prognostic indicator, the authors rformed an immunohistochemical staining of p27kip1 correlated with Ki-67 belling index and clinical parameters. p27kip1 expression was reduced variably most malignant lymphomas and inversely correlated with Ki-67 labelling index +AD0-0.0151). Regarding chemotherapeutic response, p271kip1 expression in the mplete remission group showed statistically significant difference in pression compared to the progressive disease group (p+AD0-0.0021). There were gnificant differences in survival between cases with low and high p27kip1 pression (p+AD0-0.0071). In a multivariate Cox analysis, p27kip1 expression was dependent prognostic factors as well as other known prognostic factors cluding age, grade, stage and chemotherapeutic response. In conclusion, the udy suggests that reduced expression of p27kip1 protein may play a role in the thogenesis and biologically aggressive behavior of malignant lymphomas.
Adolescence ; Adult ; Aged ; Antineoplastic Agents, Combined/therapeutic use ; Cell Cycle ; Cell Division ; Child ; Child, Preschool ; Comparative Study ; Female ; Follow-Up Studies ; Human ; Ki-67 Antigen/analysis ; Life Tables ; Lymphoma, Non-Hodgkin/pathology ; Lymphoma, Non-Hodgkin/mortality ; Lymphoma, Non-Hodgkin/drug therapy ; Lymphoma, Non-Hodgkin/chemistry+ACo- ; Male ; Microtubule-Associated Proteins/physiology ; Microtubule-Associated Proteins/analysis+ACo- ; Middle Age ; Neoplasm Proteins/physiology ; Neoplasm Proteins/analysis+ACo- ; Prognosis ; Proportional Hazards Models ; Survival Analysis ; Treatment Outcome

BACKGROUND: The ESHAP chemotherapy regimen, that is, the combination of the etoposide, methylprednisolone, high-dose cytarabine and cisplatin, has been shown to be active against relapsing or refractory non-Hodgkin's lymphoma (NHL) in previous therapeutic trials. We attempted to determine whether ESHAP therapy would be effective and well-tolerated in Korean patients. METHODS: Twenty two patients with refractory or relapsed NHLs (all aggressive types) were enrolled in this study. We retrospectively evaluated the treatment response, the survival rate and the time to progression. RESULTS: Six patients (27.3%) attained complete remission and eight patients (36.4%) attained partial remission. The overall response rate was 63.6%. The median survival duration was 15.5 months (95% confidence interval; 10.7 to 20.3 months), and the median duration of the time to progression was 8.3 months (95% confidence interval; 0.3 to 16.3 months). Myelosuppression was the major toxicity, but severe neutropenia or thrombocytopenia was rare, and renal toxicity was also infrequent. CONCLUSIONS: ESHAP regimen is effective in Korean patients suffering with relapsed or refractory NHLs, but a more effective salvage modality is needed because of the short duration of remission and the insignificant impact on long-term survival.
Treatment Failure ; Survival Analysis ; *Salvage Therapy ; Prednisone ; Neoplasm Recurrence, Local/*drug therapy/mortality ; Middle Aged ; Methylprednisolone/administration & dosage ; Male ; Lymphoma, Non-Hodgkin/*drug therapy/mortality/pathology ; Humans ; Female ; Etoposide/administration & dosage ; Disease Progression ; Cytarabine/administration & dosage ; Cisplatin/administration & dosage ; *Antineoplastic Combined Chemotherapy Protocols ; Antineoplastic Agents/administration & dosage ; Aged ; Adult ; Adolescent